Adrebloc 100 mg/10 ml IV Injection

Adrebloc 100 mg/10 ml IV Injection Uses, Dosage, Side Effects, Food Interaction and all others data.

Adrebloc 100 mg/10 ml IV Injection
Uses
Dosage
Side Effect
Precautions
Interactions
Uses during Pregnancy
Uses during Breastfeeding
Accute Overdose
Food Interaction
Half Life
Volume of Distribution
Clearance
Interaction With other Medicine
Contradiction
Storage

Trade Name	Adrebloc 100 mg/10 ml IV Injection
Generic	Esmolol Hydrochloride
Weight	100 mg/10 ml
Type	IV Injection
Therapeutic Class	Anti adrenergic agent (Beta blockers)
Manufacturer	ZAS Corporation
Available Country	Bangladesh
Last Updated:	September 24, 2024 at 5:38 am

Uses

Adrebloc 100 mg/10 ml IV Injection is a beta adrenergic blocker indicated for the short-termtreatment of: Control of ventricular rate in supraventricular tachycardia including atrial fibrillation and atrial flutter and control of heart rate in noncompensatory sinus tachycardia. Control of perioperative tachycardia and hypertension.

Dosage

Adrebloc 100 mg/10 ml IV Injection dosage

Administer intravenously. Titrate using ventricular rate or blood pressure at ≥4 minute intervals. Supraventricular tachycardia (SVT) or noncompensatory sinus tachycardia- Optional loading dose: 500 mcg per kg infused over one minute Then 50 mcg per kg per minute for the next 4 minutes Adjust dose as needed to a maximum of 200 mcg per kg per minute Additional loading doses may be administered Perioperative tachycardia and hypertension- Loading dose: 500 mcg per kg over 1 minute for gradual control (1 mg per kg over 30 seconds for immediate control). Than 50 mcg per kg per minute for gradual control (150 mcg per kg per minute for immediate control) adjusted to a maximum of 200 (tachycardia) or 300 (hypertension) mcg per kg per minute.

Side Effects

Most common adverse reactions (incidence> 10%) are symptomatic hypotension (hyperhidrosis, dizziness) and asymptomatic hypotension.

Precaution

Risk of hypotension, bradycardia, and cardiac failure: Reduce or discontinue use Risk of exacerbating reactive airway disease Diabetes mellitus: Increases the effect of hypoglycemic agents and masks hypoglycemic tachycardia Risk of unopposed alpha-agonism and severe hypertension in untreated pheochromocytoma Risk of myocardial ischemia when abruptly discontinued in patients with coronary artery disease

Interaction

Digitalis glycosides: Risk of bradycardia Anticholinesterases: Prolongs neuromuscular blockade Antihypertensive agents: Risk of rebound hypertension Sympathomimetic drugs: Dose adjustment needed Vasoconstrictive and positive inotropic effect substances: Avoid concomitant use

Pregnancy & Breastfeeding use

Pregnancy Category C. Esmolol hydrochloride has been shown to produce increased fetal resorptions with minimal maternal toxicity in rabbits when given in doses approximately 8 times the maximum human maintenance dose (300 mcg/kg/min). There are no adequate and well-controlled studies in pregnant women. Adrebloc 100 mg/10 ml IV Injection should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk and because of the potential for serious adverse reactions in nursing infants from Adrebloc 100 mg/10 ml IV Injection, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.

Contraindication

Severe sinus bradycardia Heart block greater than first degree Sick sinus syndrome Decompensated heart failure Cardiogenic shock Coadministration of IV cardiodepressant calcium-channel antagonists (e.g. verapamil) in close proximity to Esmolol hydrochloride Pulmonary hypertension Known hypersensitivity to esmolol

Special Warning

Pediatric Use: The safety and effectiveness of Adrebloc 100 mg/10 ml IV Injection in pediatric patients have not been established.Geriatric Use: Clinical studies of Adrebloc 100 mg/10 ml IV Injection did not include sufficient numbers of subjects aged 65 and over to determine whether they responded differently from younger subjects. Hepatic Impairment: No special precautions are necessary in patients with hepatic impairment because Adrebloc 100 mg/10 ml IV Injection is metabolized by red-blood cell esterases.Renal Impairment: No dosage adjustment is required for esmolol in patients with renal impairment receiving a maintenance infusion of esmolol 150 mcg/kg for 4 hours.